DAFTAR PUSTAKA

1. Prina E, Ranzani OT, Torres A. Community acquired pneumonia. Lancet. 2015; 1097–108.
2. Wiersinga WJ, Bonten MJ, Boersma WG, Jonkers RE, Aleva MR, Kullberg BJ, Schouten JA et al. Management of community acquired pneumonia in adults : 2016 guideline update from the Dutch Working Party on antibiotic policy (SWAB) and Dutch Association of Chest Physician. The Netherlands journal of medicine. 2018. 4–14.
3. Rozenbaum MH, Mangen MJ, Huitz SM, Wefr TS, Postma J. Incidence, direct cost and duration of hospitalization of patients hospitalized with community acquired pneumonia : A Nationwide retrospective claims database analysis. Journal Elsevier. 2015. 3193–99.
4. Graffelman AW, Knuistingh NA, le Cessie S, Kroes AC, Springer MP, van den Broek PJ. Pathogens involved in lower respiratory tract infections in general practice. Br J Gen Pract. 2004: 15–9.
5. Akter S, Shamsuzzaman, Jahan F. Community acquired penumonia. Int J Respir Pulm Med. 2015:1–5.
6. Van Vught LA, Scicluna BP, Wiewel MA. Co mparative Analysis of the Host Response to Community-acquired and Hospital-acquired Pneumonia in Critically Ill Patients. Am J Respir Crit Care Med. 2016: 1366–74.
7. Badan Penelitian dan Pengembangan Kesehatan. Riset kesehatan dasar (RISKESDAS). Lap Nas 2018: 1–384.
8. Fadila R. Korelasi antara kadar *tissue factor* dan *trombin-anti trombin complex* pada pasien *community acquired pneumonia* dengan sepsis. Padang: Fakultas Kedokteran Universitas Andalas; 2018.
9. Sousa RM, Postma DF, van Werkhoven CH, van Elden LJ. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015:1312–23.

10. Cecato A, Torres A. Sepsis and community-acquired pneumonia. ARH Journal. 2017. 276–92.
11. Munford RS. Severe sepsis and septic shock in Harrison's Principles of Internal Medicine, eighteenth edition. New York: McGraw-Hill. 2012. 321–29.
12. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, *et al*. The third international consensus definitions for sepsis and septic shock. JAMA.2016:802–810.
13. Tupchong K, Koyfman A, Foran M. Sepsis, severe sepsis, and septic shock: A review of the literature. African Journal of Emergency Medicine.2015.127–135.
14. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, *et al*. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. CCM Journal.2017;1–8.
15. Russell JA. Management of sepsis. NEJM journal. 2006:1-15.
16. Tsao CM, Ho ST, Wu CC. Coagulation abnormalities in sepsis. Acta Anaesthesiology Taiwanica. 2014:1– 5.
17. Levi M, Pool TV. Coagulation in Patients with Severe Sepsis. Semin Thromb Hemost. 2015:9 –15.
18. Kudo D, Hayakawa M, Ono K, Yamakawa K. Impact of non anticoagulant therapy on patients with sepsis induced disseminated intravascular coagulation : a multicenter, case control study. Pubmed Journa. 2018:13-19.
19. Gando S, Nanzaki S, Sasaki S, Aoi K, Kemmotsu C. Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Crit care med. 2005.1–9.
20. Hoppensteadt D, Williams M, Syed D, Guler N, Mosier M, Fareed J. Baseline thrombin generation markers and functional antithrombin levels in sepsis associated coagulopathies are predictive of the severity of pathogenesis. Blood journal. 2015;1–3.
21. Liu Z., Zhu H, Ma X. Heparin for treatment of sepsis: a systemic review. Critical care medicine. 2014; 26 : 135–41.

22. Wada H, Tachil J, Di Nisio M, Mathew P, Kurosawa S, Gando S, Kim HK et al. Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines. J Thromb Haemost.2013;11:761–67.
23. Hollenstein D, Dzirlo L, Eichler HG. Heparin blunts endotoxin induced coagulation activation. AHA journal.76–84.
24. Alhazzani W, Lim W, Jaeschke RZ, Murad MH, Cade J, Cook DJ. Heparin thromboprophylaxis in medical surgical critically ill patients: a systematic review and meta analysis of randomized trials. Crit care med. 2013; 41: 2088–98.
25. Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H. Antithrombin concentrate use in sepsis-associated disseminated intravascular coagulation. J Thromb Haemost. 2014:462–66.
26. Fan Y, Jiang M, Goong D, Zhou C. Efficacy and safety of low molecular weight heparin in patients with sepsis : a meta analysis of randomized controlled trials. 2016. 1−8.
27. Levi M, Tymen T, Keller, van Gorp E, Ten Cate H. Infection and inflammation and the coagulation system. Jour Cardio Res. 2003:26–39.
28. Scarlatescu E, Tomescu D, Arama SS. Sepsis associated coagulopathy.J Crit Care Med. 2016;2: 156-63.
29. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Journal of nature review: Immunology. 2013:34–46.
30. Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost 2013:559–66.
31. Semeraro N, Ammolo C, Semeraro F, Colluci M. Coagulopathy of Acute Sepsis. Jour Thromb Hemost.2015:650–58.
32. Raith EP, Udy AA, Bailey M, Mcgloughlin S, Macsaac C, Bellomo R, Pilcher DV. Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in hospital mortality among adults with suspected infection admitted to intensive care unit. JAMA. 2016;13: 290-300.

33. Baig MA, Sheikh S, Hussain E, Bakhtawar S, Khan MS, Mujtaba S, Waheed S. Comparison of qSOFA and SOFA score for predicting mortality in severe sepsis and septic shock patients in the emergency department of low middle income country. Turk J Emerg Med. 2018;4:148-51.
34. Ding R, Wang Z, Lin Y, Liu B, Zhang Z, Ma X. Comparison of a new criteria for sepsis-induced coagulopathy and International Society on Thrombosis and Haemostasis disseminated intravascular coagulation score in critically ill patients with sepsis : a retrospective study. Blood Coagul Fibrinolysis. 2018;29: 551-58.
35. Iba T, Levy JH, Raj A, Warkentin TE. Advance in the management of sepsis induced coagulopathy and disseminated intravascular coagulation. J Clin Med. 2019; 8: 728-36.
36. Versteeg HH , Heemskerk JWM , Levi M , Reitsma PH. New fundamentals in hemostasis. Physiol rev. 2012:327–358.
37. Okamoto K, Tamura T, Sawatsubashi Y. Sepsis and disseminated intravascular coagulation. J Intensive Care. 2016; 23: 1–8.
38. Asakura H. Classifying types of disseminated intravascular coagulation : clinical and animal models. Jounal of intensive care. 2014: 1–7.
39. Delabranche X, Helms J, Meziani F. Immunohaemostasis : a new view on haemostasis during sepsis. Ann Intensitve Care. 2017: 117−31.
40. Zeerleder S, Hack E, Wuilemin WA. Disseminated intravascular coagulation in Sepsis. World J Hematol. 2005:2864 – 875.
41. Zaragoza JJ, Villafuerte MV. Current approach to disseminated intravascular coagulation related to sepsis-organ failure type. World J Hematol. 2017;6:11-16.
42. Pernerstorfer T. Lepirudin blunts endotoxin –induced coagulation activation. NCBI. 2000;95:1729–734.
43. Ota S, Wada H, Abe Y, Yamada E, Sakaguchi A, Nishioka J, Hatada T. Elevated levels of prothrombin fragment 1+2 indicate high risk of thrombosis. Clinical and applied thrombosis/hemostasis. 2008 ;1–7.
44. Jespersen J, Bertina RM, Haverkate F. Laboratory technique in thrombosis : a manual. 2nd ed. Leiden. Springer : 1999. 199 – 217.

45. Vassiliou AG, Orfanos SE, Kotanidou A. Clinical assays in sepsis : prognosis, diagnosis, outcome, and the genetic basis of sepsis. 3rd ed. IntechOpen: 2017. 20-28.
46. Hirsh J. Heparin and Low Molecular Weight Heparin. BR J Hematol. 2015. 1–8.
47. Hirsh J, Sonia S, Jonathan L, Valentin F. Mechanism of Action and Phamacology of Unfractioned Heparin. Guide to Anticoagulant Therapy. 2015. 1–15.
48. Wang C, Chie C, Guo L, Wang X, Sun J, Sun B., Liu S. Heparin therapy reduced mortality in adults severe sepsis patients : A Systematic review and meta analysis. Jour Critical Care.2014 :563 – 74.
49. Zhao C, Zhang ZD, Zhang XJ, Li X, Zhu R, Ma XC: Evaluation of clinical effects on low-dose heparin therapy for sepsis. Zhonghua Nei Ke Za Zhi 2009 :566–69.
50. Lever R, Mulloy B, Page CP. Heparin-a century of progress. London (UK): Springer Heidelberg Dordrecht; 2012. 23–65.
51. Meziani F, Gando S, Vincent JL. Should all patients with sepsis receive anticoagulant. Intensive care medicine. 2017;452–56.
52. Otair HA, Gader MA, Khursyid MN, Alzeerr AH, KArim A, Al Gahtani F, AL Ahseri ZA. The Level of Tissue Factor Pathway inhibitor in Sepsis Receiving Prophylactic Enoxaparin. 2016; 33: 112−18.
53. Liu Xu, Ma X. The role of heparin in sepsis : much more than just anticoagulant. British Journal of Haematology. 2014. 1−10.
54. Lin YJ, Xiong B. The efficacy of low molecular weight heparin in the treatment of sepsis: a report of 30 clinical cases. Journal of Youjiang Medical College For Nationalities. 2012; 33: 3–5.
55. Gouya G, Palkovitz S, Kapiotis S, Madl C, Locker G, Stella A, Woltz M et al. Bioactivity of enoxaparin in critically ill patients with normal renal function. Br J Clin Pharmacol.2012;74: 806-14.
56. Ai YH, Zhang LN, Gong H, Xu DM, Zhao SP, Chen JH: Clinical study of low molecular weight heparin therapy for sepsis. Blood Coagul Fibrinolysis. 2007:219–26.

57. Robinson S, Zincuk A, Larsen UL, Ekstrom C, Nybo M, Rasmussen B, Toft P. A comparative study of varying dose of enoxaparin for thromboprophylaxis in critically ill patients: a double blinded, randomized controlled trial. Critical Care. 2013;17: 1-8.
58. Zenahlikova Z, Kvaniska J, Kudrnova Z, Sudrova M, Brzezkova R, Mazoch J, Malikova I *et al*. FXa Inhibition and coagulation changes during dvt prophylaxis by enoxaparin over the course of a 15 day follow up in septic patients. Clin and App Thromb. 2015; 16: 584-90.
59. Liu XL, Wang XZ, Liu X, Hao Dong, Jaladat Y, Lu Feng *et al*. Low dose heparin as treatment for early disseminated intravascular coagulation during sepsis: A Prospective clinical study.Exp and Therau Med. 2014;7: 604-08.
60. Grossert A, Spiro E, Beynon J, Rodgers G. Enoxaparin : A Low Molecular Weight Heparin Suppresses Prothrombin Activation More Effectively than Unfractionated Heparin in Patient Treated for Venous Embolism. 1997; 89: 245-54.
61. Zarychanski R, Abou-Setta, Kanji S, Turgeon F, Kumar A, Houston DS, Rimmer E et al. The efficacy and safety of heparin in patients with sepsis : a systematic review and metaanalysis. Crit care med. 2015;43: 511-18.
62. Kinasewitz G, Yan B, Basson B,Comp P, Russell J, Cariou A, Um S et al. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative microorganism. Clin Care J. 2004;8: 82-90.
63. Gando S, Iba T, Thachil J. Anticoagulant therapy for sepsis associated disseminated intravascular coagulation: the view from Japan. Throm and Haem Jour. 2014;12:1010-19.
64. Hoppensteadt D, Tsuruta K, Cunanan J, Hirman J, Kaul I, Osawa Y, Fareed J. Thrombin generation mediators and markers in sepsis associated coagulopathy and their modulation by recombinant thrombomodulin. Clin Appl Thromb Hemost. 2014;20: 129-35.

65. Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson B, Brandt JT, Sundin P *et al*. Treatment effect of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. Jour Thromb and Haem. 2004;2:1924-33.
66. Umemura Y, Yamakawa K, Ogura H, Yuhara H, Fujimi S. Efficacy and safety of anticoagulant therapy in three specific population with sepsis : a meta analysis of randomized controlled trials. 2015;14:518-30.